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OBJECTIVES We sought to elucidate the clinical factors related to the development of no-reflow
phenomenon after successful coronary reperfusion in patients with an acute myocardial
infarction (AMI).
BACKGROUND Myocardial contrast echocardiography revealed that the no-reflow phenomenon is observed
in some patients with a reperfused AMI, and those patients usually have poor functional and
clinical outcomes. It is still unknown what clinical factors are related to the development of
the no-reflow phenomenon.
METHODS Myocardial contrast echocardiography was performed 15 min after successful coronary
reperfusion therapy in 199 patients with an anterior wall AMI who underwent successful
coronary reperfusion with primary coronary angioplasty within 24 h after the onset of AMI.
Multiple logistic regression analysis was used to identify independent predictors of the
no-reflow phenomenon.
RESULTS Seventy-nine patients showed the no-reflow phenomenon. Univariate analysis indicated that
pre-infarction angina within 48 h before symptom onset, Killip class, Thrombolysis in
Myocardial Infarction flow grade 0 on the initial coronary angiogram, the number of
abnormal Q-waves and the wall motion score (WMS) on the echocardiogram obtained at
hospital admission are related to the no-reflow phenomenon. Multivariate logistic regression
analysis revealed that all of these factors, except for Killip class, are independent predictive
factors of the no-reflow phenomenon.
CONCLUSIONS Development of the no-reflow phenomenon is related to the severity of myocardial damage
(number of Q-waves), the size of the risk area (WMS) and the occlusion status of
infarct-related artery. In addition, ischemic preconditioning (pre-infarction angina) seems to
be the factor that attenuates the no-reflow phenomenon. (J Am Coll Cardiol 2001;38:472–7)
© 2001 by the American College of Cardiology
Coronary reperfusion therapy has improved the prognosis of
patients with acute myocardial infarction (AMI). However,
successful recanalization, as demonstrated by angiography,
does not necessarily guarantee adequate myocardial salvage
in all patients (1,2). We have used myocardial contrast
echocardiography (MCE) to demonstrate that the no-
reflow phenomenon is observed in ;30% of patients with a
reperfused anterior wall AMI (3). These patients have poor
functional recovery and more frequently manifest post-AMI
complications, as compared with those with good reflow (4).
Several clinical factors, such as the age of the patient (5),
the presence of congestive heart failure (5,6), the time
elapsed from the onset of AMI to treatment (5,7), collateral
circulation (7,8), pre-infarction angina (9,10) and ST seg-
ment re-elevation after coronary reperfusion (11,12), have
been reported to affect the functional outcomes and clinical
prognoses of patients with AMI. Although these factors
may also affect the development of microvascular dysfunc-
tion, their relationship to the no-reflow phenomenon re-
mains unknown. In the present study, we compared the
clinical, hemodynamic and electrocardiographic (ECG)
variables of patients with the no-reflow phenomenon with
those of patients without it to derive the predictive factors of
the no-reflow phenomenon after a reperfused anterior wall
AMI.
METHODS
Study group. Between July 1992 and January 1999, 265
consecutive patients with their first AMI underwent pri-
mary percutaneous transluminal coronary angioplasty
(PTCA) or stent implantation, or both, of the totally or
subtotally occluded coronary artery (Thrombolysis In Myo-
cardial Infarction [TIMI] flow grade 0 or 1) within 24 h of
symptom onset of AMI and underwent MCE in the
catheterization laboratory. The diagnosis of AMI was based
on chest pain lasting $30 min, ST segment elevation
$2 mm in at least two contiguous ECG leads and a greater
than threefold increase in serum creatine kinase (CK) levels.
Sixty-six patients were excluded because of a poor echocar-
diographic image (n 5 33), spontaneous recanalization of
the culprit lesion (TIMI flow grade $2) at the time of the
initial coronary angiographic study (n 5 20), allergy to
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ioxaglate (n 5 7) and unsuccessful angioplasty (n 5 6).
Therefore, the final study group consisted of 199 patients.
The study protocol was approved by the hospital’s Ethics
Committee. One of the investigators obtained written,
informed consent from each patient before cardiac cathe-
terization.
Study protocol. We recorded the 12-lead ECG on hospi-
tal admission and then performed two-dimensional echo-
cardiography. We recorded the apical and parasternal views.
We defined the risk area as myocardial segments showing
dyskinesia, akinesia or severe hypokinesia.
Aspirin (243 mg) was given orally at least 30 min before
coronary angiography. After administration of intravenous
heparin (100 U/kg), we performed coronary angiography
using the right femoral approach to determine the culprit
lesion and collateral channels. Collateral channels were
graded according to the report by Rentrop et al. (13), and
good collateral flow was defined as grade 2 or 3. We
performed PTCA on the culprit lesion by using
appropriate-sized balloon catheters. We repeated PTCA or
implanted a stent to achieve a residual diameter stenosis
,50%. At a mean time of 15 min after the last PTCA, we
performed MCE, as previously reported (3,4). In brief, we
injected 2 ml of sonicated ioxaglate (Hexabrix-320, Tanabe,
Tokyo, Japan) containing microbubbles of a mean size of
12 mm into the left coronary artery while recording the
two-dimensional echocardiograms using a mechanical sec-
tor scanner (model SAL-38B, Toshiba, Tokyo, Japan or
SONOS 100, Agilent Technologies, Palo Alto, California;
carrier frequency of 3.5 MHz). The MCE images, including
the parasternal short-axis view at the mid-papillary muscle
level and the apical two-chamber view, were recorded on
1.25-cm VHS videotape.
Analysis of echocardiographic data. Two independent
observers who had no knowledge of the patients’ data
evaluated wall motion of 16 myocardial segments, as en-
dorsed by the American Society of Echocardiography (14).
The wall thickening of each myocardial segment was scored
as follows: 4 5 dyskinesia; 3 5 akinesia; 2 5 severe
hypokinesia; 1 5 hypokinesia; and 0 5 normokinesia or
hyperkinesia. The wall motion score (WMS) was calculated
as the sum of the scores within the area at risk.
Two experienced echocardiographers who had no knowl-
edge of the patients’ data analyzed the MCE image to
identify the area of the no-reflow phenomenon, as described
elsewhere (3,4). In brief, we defined the no-reflow zone on
end-diastolic images as contrast perfusion defects after
PTCA. We quantified the area of no-reflow as its ratio to
the risk area at the baseline study. When the ratio exceeded
0.25, myocardial reperfusion in the corresponding segment
was considered incomplete (MCE no-reflow). If this ratio
was #0.25, we considered myocardial reperfusion was
adequate (MCE reflow) (Fig. 1). Our previous study dem-
onstrated the high reproducibility of measuring the size of
the contrast defect (3).
Analysis of ECG data. On the 12-lead ECG recorded
before PTCA, we measured the number of infarct-related
Q-waves in the precordial leads. We also recorded the
12-lead ECG repeatedly during and after the angioplasty
procedure. If the ST segments in the leads corresponding to
the infarct-related lesion showed additional elevation
(.2 mm) shortly after reperfusion, and this elevation
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
ATP 5 adenosine triphosphate
CK 5 creatine kinase
ECG 5 electrocardiogram or electrocardiographic
MCE 5 myocardial contrast echocardiography
PTCA 5 percutaneous transluminal coronary angioplasty
TIMI 5 Thrombolysis In Myocardial Infarction
WMS 5 wall motion score
Figure 1. Representative myocardial contrast echocardiography (MCE) images in patients with an anterior wall acute myocardial infarction (apical
two-chamber view). (Left) Good contrast enhancement, with injection of sonicated contrast agent into the left coronary artery, was observed within the
area at risk, and this patient had reflow on MCE. (Right) In contrast, a substantial amount of contrast defect was observed within the area at risk (area
between arrows), even after successful opening of the culprit lesion, and this patient had no-reflow on MCE.
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persisted at least 1 h after reperfusion, we designated it as
ST segment re-elevation.
Analysis of clinical history. Physical examinations were
precisely performed on hospital admission by at least one of
the staff physicians, and the state of congestive heart failure
was expressed as the Killip class. A detailed clinical history
in each study patient was obtained by a staff physician. The
onset of AMI was defined as the initiation of chest pain or
chest discomfort persisting $30 min. Cardiac symptoms
lasting ,30 min were defined as a sign of angina pectoris,
and angina occurring #48 h before the onset of infarction
was defined as pre-infarction angina (10). A clinical history
of risk factors, such as diabetes mellitus, hypertension,
hyperlipidemia and smoking, was determined from a patient
interview or medical records.
Statistics. All data are expressed as the mean value 6 SD.
We made comparisons by using one-way analysis of vari-
ance for continuous variables, and the significance of the
difference was calculated by using the Scheffe´ F test for
factor analysis. Categorical variables were compared by
using the chi-square test. Univariate and multivariate logis-
tic regression analyses were used to identify independent
predictors for the development of the no-reflow phenome-
non. Variables used for analysis included age, gender,
coronary risk factors, Killip class, pre-infarction angina,
distributions of the culprit lesion, elapsed time from symp-
tom onset to reperfusion, number of Q-waves in the
precordial leads, ST segment re-elevation after PTCA,
WMS on the echocardiogram, presence of good collateral
channels and occlusion status in the culprit lesion. Differ-
ences were considered significant at p , 0.05. Statistical
analysis was performed using StatView, version 5.0 (SAS
Institute, Cary, North Carolina).
RESULTS
Patient characteristics. There were 199 study patients
(mean age 59 6 10 years [range 25 to 86]; 158 men and 41
women). The culprit lesion was at the proximal portion of
the left anterior descending coronary artery in 107 patients
and at the middle portion in 92 patients. The mean time
from symptom onset to coronary reperfusion was 6.1 6
4.3 h. A stent was implanted in 10 patients. The peak CK
level was 2,663 6 1,961 IU/l.
Using MCE, a substantial amount of no-reflow was
observed within the risk area in 79 patients (39.6%) (MCE
no-reflow), and the remaining 120 patients were classified
as having reflow (MCE reflow). The patients with MCE
reflow showed lower peak CK value than those with MCE
no-reflow (p , 0.0001). There were no significant differ-
ences in age, gender and coronary risk factors between the
two subgroups (Table 1). The elapsed time from symptom
onset to coronary reperfusion was also comparable between
two subgroups.
Among the 120 patients with MCE reflow, 61 (50.8%)
had one or more episodes of angina #48 h before symptom
onset, whereas only 25 patients (31.6%) with MCE no-
reflow had episodes of pre-infarction angina (p 5 0.008).
On hospital admission, the patients with MCE no-reflow
had a significantly higher Killip class than those with MCE
reflow.
Determinants of the no-reflow phenomenon. The WMS
and number of infarct-related Q-waves in the ECG precor-
dial leads before PTCA were significantly greater in patients
with MCE no-reflow than in those with MCE reflow. The
incidence of transient ST segment re-elevation shortly after
coronary reperfusion was comparable between two sub-
groups. There was no difference in the distribution of culprit
lesions between two subgroups. Complete occlusion (TIMI
flow grade 0) of the left anterior descending coronary artery
was more frequent in the patients with MCE no-reflow
than in those with MCE reflow at the initial coronary
angiographic study. There were no significant differences in
the incidence of good collateral channels between two
subgroups.
To determine the independent factors related to the
development of the no-reflow phenomenon, we performed
multiple logistic regression analysis. Univariate analysis
revealed that the absence of pre-infarction angina, Killip
class, complete occlusion of the culprit lesion, number of Q-







Age (years) 58 6 10 60 6 10 0.17
Gender (M/F) 99/21 59/20 0.18
Risk factors
Diabetes mellitus 23.3 20.2 0.61
Hypertension 24.1 23.4 0.39
Hyperlipidemia 15.0 16.5 0.78
Smoking 30.0 25.3 0.47
Symptom onset to
reflow time (h)




Peak CK (IU/l) 1,869 6 1,303 3,883 6 2,173 ,0.0001
Killip class








WMS 15.5 6 5.1 19.0 6 5.1 ,0.0001
Stent implantation 6 4 0.98
Culprit lesion in proximal LAD 48.3 62.0 0.06
TIMI flow grade 0 at initial
coronary angiography
61.7 87.3 ,0.0001
Good collateral channels* 18.3 22.8 0.44
*Those graded as 2 or 3. Data are presented as the mean value 6 SD or number (%)
of patients.
CK 5 creatine kinase; ECG 5 electrocardiogram; F 5 female; LAD 5 left
anterior descending coronary artery; M 5 male; MCE 5 myocardial contrast
echocardiography; TIMI 5 Thrombolysis In Myocardial Infarction trial; WMS 5
wall motion score.
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waves and WMS were independent predictors of the no-
reflow phenomenon. Multivariate logistic regression analy-
sis revealed that all of these factors, except for Killip class,
are independent predictive factors of the no-reflow phe-
nomenon (Table 2). The number of Q-waves has the
highest Wald’s chi-square value, followed by WMS, com-
plete occlusion and absence of pre-infarction angina, sug-
gesting that the number of Q-waves is the strongest factor
to predict the no-reflow phenomenon.
DISCUSSION
In the present study, we investigated the factors related to
the no-reflow phenomenon in 199 patients with a first
anterior wall AMI. Univariate analysis indicated that the
absence of pre-infarction angina, Killip class, number of Q-
waves, WMS and TIMI flow grade 0 at the initial coronary
angiographic study were the factors related to the no-reflow
phenomenon. Multivariate analysis revealed that all of these
factors, except for Killip class, are independent factors
related to the no-reflow phenomenon. Thus, both greater
size of the risk area and more severe myocardial damage at
the moment of coronary reperfusion are closely related to
the no-reflow phenomenon. In contrast, both residual
coronary flow and preconditioning seem to suppress the
progression of microvascular damage. To the best of our
knowledge, this is the first report to reveal the factors
relevant to the progression of microvascular dysfunction.
Preconditioning angina. Pre-infarction angina shortly be-
fore the onset of AMI limits infarct size and promotes
cardiac functional recovery in reperfused patients with AMI
(9,10), although its mechanism has not yet been fully
understood. Our data demonstrate that pre-infarction an-
gina may attenuate the development of the no-reflow
phenomenon, and thus preserve both microvascular func-
tion and tissue perfusion after reperfusion. Komamura et al.
(15) measured the temporal changes in coronary vein flow in
patients with AMI and indicated that pre-infarction angina
is a factor that prevents a progressive decrease in coronary
flow, which implies the no-reflow phenomenon, after suc-
cessful thrombolysis. Our study indicates that augmentation
of myocardial perfusion is another mechanism of cardiopro-
tection.
Several mechanisms are suggested for the protection of
the coronary microvasculature by preconditioning. Experi-
mental studies indicated that ischemic preconditioning pre-
vents endothelial dysfunction after ischemia-reperfusion
(16,17). Plugging of capillaries with leukocytes is one of the
major mechanisms of microvascular dysfunction (18). Isch-
emic preconditioning reduces the adhesion of leukocytes
after ischemia-reperfusion (19–21), probably through a
decreased expression of endothelial adhesion molecules,
such as intercellular adhesion molecule-1, on the cellular
membrane surface (21). Inhibition of leukocyte adhesion
might preserve endothelial function during ischemia (21), or
vice versa (20).
Severity of myocardial damage before coronary reperfu-
sion. Both the number of Q-waves and WMS on hospital
admission were identified as factors related to the no-reflow
phenomenon. This result indicates that both the size of the
risk area and the severity of myocardial damages seem to be
determinants of the no-reflow phenomenon. The WMS
before reperfusion is mainly determined by the size of the
risk area, because the risk area always shows dyskinesia or
akinesia (22). Clinical and experimental studies have dem-
onstrated that the size of the risk area is well correlated with
the infarct size after reperfusion therapy (7,23). Myocardial
necrosis extends from the center of the area at risk to the
peripheral zone after coronary occlusion. The functional
border zone is in the marginal zone of the risk area, and
myocardial perfusion due to the diffusion from the normal
Table 2. Univariate and Multivariate Predictors of the No-Reflow Phenomenon
Univariate Analysis Multivariate Analysis
Chi-Square* p Value Chi-Square* p Value OR (95% CI)
Age 1.92 0.16 1.17 0.28 1.02 (0.98–1.06)
Gender 1.76 0.18 0.34 0.56 0.76 (0.30–1.90)
Diabetes mellitus 0.26 0.61 0.001 0.98 0.99 (0.39–2.48)
Hypertension 0.73 0.39 0.84 0.36 1.60 (0.60–4.12)
Hyperlipidemia 0.08 0.78 0.61 0.43 0.64 (0.21–1.96)
Smoking 0.52 0.47 0.34 0.56 0.78 (0.33–1.81)
Symptom onset to reflow time 0.67 0.41 2.28 0.13 0.93 (0.85–1.02)
Absence of pre-infarction angina 7.03 0.008 4.52 0.03 2.15 (1.06–4.37)
Killip class 6.46 0.01 3.01 0.08 1.77 (0.93–3.36)
No. of Q-waves on ECG 20.1 ,0.0001 12.4 0.0004 1.52 (1.20–1.92)
Transient ST segment re-elevation 1.91 0.17 0.71 0.40 1.40 (0.65–2.97)
WMS 18.4 ,0.0001 7.31 0.007 1.12 (1.03–1.21)
TIMI flow grade 0 at initial
coronary angiography
14.2 0.0002 5.17 0.02 2.90 (1.16–7.23)
Culprit lesion in proximal LAD 3.57 0.06 0.40 0.53 0.79 (0.38–1.65)
Good collateral channels† 0.59 0.44 0.62 0.42 0.70 (0.30–1.66)
*Denotes Wald’s chi-square value. †Those graded as 2 or 3.
CI 5 confidence interval; OR 5 odds ratio; other abbreviations as in Table 1.
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peripheral myocardium plays an important role in preserv-
ing myocardial viability in this area. If the risk area is too
large to be perfused with collateral or diffusive blood flow,
the size of infarction would be greater. Because the no-
reflow zone is correlated with the areas of necrosis (24), the
greater the size of the area at risk could lead to the area of
no-reflow, and thus the greater the size of the infarct zone.
The greater number of Q-waves implies the broader
transmural damage in the anterior wall before coronary
reperfusion. In canine studies, Kloner et al. (24,25) found
that the no-reflow zone is located within the areas of
necrosis and suggested that some kind of no-reflow phe-
nomenon is already established before reperfusion. Our
recent study using the Doppler guide wire demonstrated
that the coronary flow velocity pattern specific to substantial
no-reflow is found at the moment of reperfusion in some
patients (26). These patients had a larger number of Q-
waves before reperfusion, as compared with those who
gradually developed a specific flow pattern. The present
results also suggest that the no-reflow phenomenon has
already been established before reperfusion, at least in some
patients.
Residual coronary flow is a factor that attenuates the
development of myocardial damage in patients with AMI
(27,28). The present study showed that little residual
coronary flow, such as TIMI flow grade 1, could prevent the
development of the no-reflow after coronary reperfusion. A
supply of coronary blood flow before reperfusion might
protect the microvasculature, as well as the myocardium. In
contrast, collateral channels on coronary angiography are
not an independent determinant of the no-reflow phenom-
enon, possibly because the angiographic collateral flow
grade does not always reflect myocardial perfusion through
collateral channels (29).
Study limitations. The presence or absence of pre-infarc-
tion angina was assessed from a clinical history obtained by
staff physicians, but ischemic episodes are not necessarily
symptomatic. The significance of silent ischemia could not
be evaluated in our study. We could not successfully analyze
the effects of the drugs that patients had received before the
onset of AMI. Drugs such as glyburide, which could affect
a patient’s prognosis after AMI (30), might also affect the
development of the no-reflow phenomenon, because it
inhibits the adenosine triphosphate (ATP)-sensitive K1
(KATP) channel and might attenuate ischemic precondition-
ing (31). We also did not evaluate the severity of coronary
risk factors, which might be related to the development of
the no-reflow phenomenon. The impact of stents on coro-
nary microvascular function was not discussed because the
number of patients with stent implants was too small.
Clinical implications. No-reflow after coronary reperfu-
sion is associated with poor functional and clinical out-
comes; thus, it would be useful, for risk stratification, to
identify patients with a high risk of no-reflow. Recent
reports have revealed that nicorandil (32) or adenosine (33)
can prevent the development of the no-reflow phenomenon
after a patient has had a reperfused AMI. Adenosine plays
an important role in preconditioning by opening the KATP
channel through A1 receptors (34,35), and nicorandil is also
a potent opener of KATP channels (34). Thus, either
nicorandil or adenosine might prevent the development of
no-reflow through the cellular mechanisms of ischemic
preconditioning.
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